期刊文献+

血管性血友病因子研究进展 被引量:7

下载PDF
导出
摘要 血管性血友病因子(v WF)是血管内皮细胞和骨髓巨核细胞合成的一种糖蛋白,在1期和2期止血中都起着重要作用,如缺乏将导致患者出现血管性血友病(v WD)。v WF可被AD-AMTS13裂解以失去活性,凝血酶敏感蛋白-1可能参与了这个调节过程。v WF水平受多种遗传和环境因素影响,其中ABO血型影响较大。v WF主要通过A1和A3区与血小板GPlb和胶原结合。深入研究v WF的合成、分泌、降解和清除机制,以及v WF结构和功能的关系,有助于寻找新的止血与血栓防治途径。
作者 谢飞 王鸿利
出处 《国际检验医学杂志》 CAS 2006年第7期622-624,共3页 International Journal of Laboratory Medicine
  • 相关文献

参考文献14

  • 1Mendolicchio GL, Ruggeri ZM. New perspectives on yon Willebrand factor functions in hemostasis and thrombosis. Semin Hematol, 2005, 42(1): 5-14.
  • 2Haberichter SL, Merricks EP, Fahs SA, et al. Re-establishment of VWF-dependent Weibel-Palade bodies in VWD endothelial cells.Blood, 2005, 105(1): 145-152.
  • 3Padilla A, Moake JL, Bernardo A, et al. P-selectin anchors newly released ultralarge yon Willebrand factor multimers to the endothelial cell surface. Blood, 2004, 103(6): 2150-2156.
  • 4Lopez JA, Dong JF. Cleavage of yon Willebrand factor by AD-AMTS-13 on endothelial cells. Semin Hematol, 2004, 41(1) : 15-23.
  • 5Nishio K, Anderson PJ, Zheng XL, et al. Binding of platelet glycoprotein Ibalpha to yon Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13. Proc NatlAcad Sci USA, 2004, 101(29) :10578-10583.
  • 6Soejima K, Nakagaki T. Interplay between ADAMTS13 and von Willebrand factor in inherited and acquired thrombotic microangiopathies. Semin Hematol, 2005, 42(1) : 56-62.
  • 7Bowen DJ, Collins PW, Lester W, et al. The prevalence of the cysteine1584 variant of yon Willebrand factor is increased in type 1 von Willebrand disease: co-segregation with increased susceptibility to ADAMTS13 proteolysis but not clinical phenotype. Br J Haematol, 2005, 128(6): 830-836.
  • 8Pimanda JE, Ganderton T, Maekawa A, et al. Role of thrombospondin-1 in control of yon Willebrand factor multimer size in mice. J Biol Chem, 2004, 279(20).. 21439-21448.
  • 9Lenting PJ, Westein E, Terraube V, et al. An experimental model to study the in vivo survival of yon Willebrand factor. Basic aspects and application to the R1205H mutation. J Biol Chem, 2004, 279(13) : 12102-12109.
  • 10Favaloro EJ, Lillicrap D, Lazzari MA, et al. yon Willebrand disease: laboratory aspects of diagnosis and treatment. Haemophilia,2004, 10(Suppl 4): 164-168.

同被引文献57

  • 1陈永利,张敬霞,袁志明,毕研永,王佩显.纤溶酶原激活物及其抑制剂-1的血浆含量测定在急性肺血栓栓塞症中的意义[J].中华急诊医学杂志,2005,14(3):191-194. 被引量:12
  • 2宋丽洁,丁琪,姚桂玲,王海燕.抗凝血酶活性变化的研究及临床意义[J].血栓与止血学,2006,12(4):180-182. 被引量:14
  • 3Mcmillan R.The pathogenesis of chronic immune thrombocytopenic purpura[J].Semin Hematol,2007,44(4 Suppl 5):S3.
  • 4Tomer A,Friese P,Conklin R,et al.Flow cytometric analysis of megakaryocytes from patients with abnormal platelet counts[J].Blood,1989,74(2):594.
  • 5Tomer A.Human marrow megakaryocyte differentiation:multiparameter correlative analysis identifies von Willebrand factor as a sensitive and distinctive marker for early (2N and 4N) megakaryocytes[J].Blood,2004,104(9):2722.
  • 6Leven R M.Differential regulation of integrin-mediated proplatelet formation and megakaryocyte spreading[J].J Cell Physiol,1995,163(3):597.
  • 7Leven R M,Tablin F.Extracellular matrix stimulation of guinea pig megakaryocyte proplatelet formation in vitro is mediated through the vitronectin receptor[J].Exp Hematol,1992,20(11):1316.
  • 8Mcmillan R.Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective platelet production[J].Hematol Oncol Clin North Am,2009 23(6):1163.
  • 9Houwerzijl E J,Blom N R,van der Want J J,et al.Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura[J].Blood,2004,103(2):500.
  • 10Schick P K,Walker J,Profeta B,et al.Synthesis and secretion of von Willebrand factor and fibronectin in megakaryocytes at different phases of maturation[J].Arterioscler Thromb Vasc Biol,1997,17(4):797.

引证文献7

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部